Featured Research

from universities, journals, and other organizations

New Rheumatoid Arthritis Drug Developed At UCSD Promises Improved Treatment Options

Date:
October 16, 2005
Source:
University of California - San Diego
Summary:
Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

Related Articles


Salvatore Albani, M.D., Ph.D, professor of medicine andpediatrics and Director of the Translational Research Unit of theClinical Investigation Institute (CII) at the UCSD School of Medicine,recently presented a summary of the findings at the “Frontiers ofClinical Investigation Symposium.” The symposium, sponsored by the CIIand Nature Medicine, was held in La Jolla, California in September.

Thenew drug, dnaJP1, is a peptide derived from a naturally occurringprotein, dnaJ, which generates inflammation in RA patients, whoseinflammatory-control mechanisms are impaired. The impairment causes thebody’s T cells – which trigger inflammation to kill and clear foreignpathogens in the body – to attack the body’s own tissues.

“Inessence, we re-educated the immune system T cells to be tolerant of thednaJP1 amino acid sequence, which would usually contribute toinflammation in rheumatoid arthritis patients,” Albani said.

DnaJP1works by resetting the ability of the patient’s immune system totolerate dnaJ, thus transforming a potentially damaging trigger into atool for controlling the disease. Oral ingestion of dnaJP1 is key,because the mucosal immune system found in the gut has the ability to“teach” the body to view a protein as one that isn’t dangerous orforeign. Much as food is ingested into the body and not rejected, thebody tolerates dnaJP1.

Current medications for treating RA rangefrom anti-inflammatory drugs, such as aspirin, to corticosteroids andmedicines that alleviate symptoms by suppressing or killing the body’simmune response, basically crippling the body’s ability to defenditself against other infectious diseases or cancer.

“Such drugsare costly, have potentially dangerous side effects and areinconvenient to administer,” Albani said. “Our drug leaves thepatient’s natural immune responses intact. This differs profoundly fromwhat is currently available to patients.”

DnaJP1 was foundeffective in a double-blind, placebo-controlled trial sponsored by theNational Institutes of Health, which took place between 2000 and 2005and involved 160 patients enrolled in centers nationwide includingUCSD, Stanford University, Johns Hopkins University, the Mayo Clinic,and Virginia Mason Medical Center in Seattle. The technology wasdeveloped at UCSD and has been licensed for further development toAndroclus Therapeutics, a biotechnology company located in San Diegoand Milan, Italy. Dr. Albani is one of the company’s co-founders.

Patientsreceived 25mg of dnaJP1 daily by mouth for six months, and thetreatment was found to be safe and well-tolerated. When compared with aplacebo, patients in the treatment group experienced lessening ofsymptoms such as swollen joints, tenderness, pain and decreasedmobility. Improvement was particularly significant at the follow upvisits, indicating a lasting effect of the drug. Efficacy wasquantified in data generated from physicians, patients andlaboratories, measuring improvement according to standards set by theAmerican College of Rheumatology (ACR) from the beginning to laterpoints in the trial. For instance, “ACR 20” indicates a 20% improvementin standardized symptoms. ACR 20 response was in the 50-55% range; ACR50 in the 30-40% range; and ACR 70 in the 15-20% range of patientscompleting the trial.

Rheumatoid arthritis, or inflammation ofthe joints, is a chronic, painful disease affecting one percent of theU.S. population, or more than 2 million people. It occurs three timesmore often in women than men, targeting people of every age. Thecondition simultaneously strikes joints on both sides of the body, suchas the hands or feet or knees but can also affect the skin, eyes,lungs, heart, blood, nerves or kidneys. It is an incurable disease,with most therapies focusing on symptom relief.

“Although thecurrent available drugs pose risks to patients, the first two trials ofdnaJP1 have not raised any significant safety concerns and offer animproved treatment option for patients with rheumatoid arthritis,” saidAlbani. The next step, according to Albani, is to get approval andfunding to move into Phase III clinical trials.

“This is a veryexciting and novel therapeutic approach, which holds the promise to bean entirely new type of immunomodulatory drug – one that can shape apatient’s immune system, rather than suppressing it,” said Gary S.Firestein, M.D., Director of CII (http://cii.ucsd.edu/), which providesUCSD faculty with an infrastructure to support the translation offundamental biology into novel therapeutic interventions. “It is alsoan Institute success story because it represents a true ‘bench tobedside’ research model.”


Story Source:

The above story is based on materials provided by University of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Diego. "New Rheumatoid Arthritis Drug Developed At UCSD Promises Improved Treatment Options." ScienceDaily. ScienceDaily, 16 October 2005. <www.sciencedaily.com/releases/2005/10/051015091721.htm>.
University of California - San Diego. (2005, October 16). New Rheumatoid Arthritis Drug Developed At UCSD Promises Improved Treatment Options. ScienceDaily. Retrieved December 17, 2014 from www.sciencedaily.com/releases/2005/10/051015091721.htm
University of California - San Diego. "New Rheumatoid Arthritis Drug Developed At UCSD Promises Improved Treatment Options." ScienceDaily. www.sciencedaily.com/releases/2005/10/051015091721.htm (accessed December 17, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, December 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins